KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Leases (2017 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Leases for 15 consecutive years, with $189.3 million as the latest value for Q1 2026.

  • For Q1 2026, Leases fell 4.02% year-over-year to $189.3 million; the TTM value through Mar 2026 reached $189.3 million, down 4.02%, while the annual FY2025 figure was $194.9 million, 1.97% up from the prior year.
  • Leases hit $189.3 million in Q1 2026 for Alnylam Pharmaceuticals, down from $194.9 million in the prior quarter.
  • Across five years, Leases topped out at $228.8 million in Q1 2022 and bottomed at $189.3 million in Q1 2026.
  • Average Leases over 5 years is $203.5 million, with a median of $198.3 million recorded in 2024.
  • Year-over-year, Leases dropped 9.11% in 2024 and then rose 1.97% in 2025.
  • Alnylam Pharmaceuticals' Leases stood at $215.1 million in 2022, then dropped by 7.16% to $199.7 million in 2023, then decreased by 4.3% to $191.1 million in 2024, then grew by 1.97% to $194.9 million in 2025, then dropped by 2.88% to $189.3 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $189.3 million, $194.9 million, and $191.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.